Cargando…

Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder

Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of...

Descripción completa

Detalles Bibliográficos
Autores principales: Castaldelli-Maia, João M., Malbergier, André, de Oliveira, Adriana B. P., Amaral, Ricardo A., Negrão, André B., Gonçalves, Priscila D., Ventriglio, Antonio, de Berardis, Domenico, de Antonio, Juliana, Firigato, Isabela, Gattás, Gilka J. F., de Toledo Gonçalves, Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533258/
https://www.ncbi.nlm.nih.gov/pubmed/34680127
http://dx.doi.org/10.3390/biom11101495
_version_ 1784587269383913472
author Castaldelli-Maia, João M.
Malbergier, André
de Oliveira, Adriana B. P.
Amaral, Ricardo A.
Negrão, André B.
Gonçalves, Priscila D.
Ventriglio, Antonio
de Berardis, Domenico
de Antonio, Juliana
Firigato, Isabela
Gattás, Gilka J. F.
de Toledo Gonçalves, Fernanda
author_facet Castaldelli-Maia, João M.
Malbergier, André
de Oliveira, Adriana B. P.
Amaral, Ricardo A.
Negrão, André B.
Gonçalves, Priscila D.
Ventriglio, Antonio
de Berardis, Domenico
de Antonio, Juliana
Firigato, Isabela
Gattás, Gilka J. F.
de Toledo Gonçalves, Fernanda
author_sort Castaldelli-Maia, João M.
collection PubMed
description Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the present study aims to investigate the role of AME genotype variants in the treatment of AUD with naltrexone. Methods: We carried out a 12-week longitudinal clinical trial based on the treatment of AUD patients with naltrexone (N = 101), stratified by different alcohol metabolization genotypes. Genotyping was performed after the inclusion of the patients in the study, based on the individual presence of single nucleotide polymorphisms (SNPs) in the ADH (alcohol dehydrogenase)1B (ADH1B*2 and ADH1B*3), ADH1C (ADHC*1) and ALDH (aldehyde dehydrogenase) 2 (ALDH2*2) genes. The outcome of alcohol use has been monitored employing the timeline follow-back during the treatment. Results: The ADH1C*1 (Ile350Val, rs698) and ALDH2*2 (Glu504Lys, rs671) polymorphisms were associated with a better response to naltrexone treatment, whereas the ADH1B*3 (Arg370Cys, rs2066702) allelic variant showed a negative outcome. Conclusions: The present study explores a genomic setting for the treatment of AUD with naltrexone. According to our findings, the association between ADH1C*1 and ALDH2*2 variants and better outcomes suggests a successful treatment, whereas the ADH1B*3 mutated allele might lead to an unsuccessful treatment. Further studies should be performed to investigate the relationship between alcohol metabolizing genotypes, the family history of alcohol use disorders and the effect of naltrexone on the outcomes. Genotyping may be a valuable tool for precision-medicine and individualized approach, especially in the context of alcohol use disorders. The small number of subjects was the main limitation of the present study.
format Online
Article
Text
id pubmed-8533258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85332582021-10-23 Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder Castaldelli-Maia, João M. Malbergier, André de Oliveira, Adriana B. P. Amaral, Ricardo A. Negrão, André B. Gonçalves, Priscila D. Ventriglio, Antonio de Berardis, Domenico de Antonio, Juliana Firigato, Isabela Gattás, Gilka J. F. de Toledo Gonçalves, Fernanda Biomolecules Article Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the present study aims to investigate the role of AME genotype variants in the treatment of AUD with naltrexone. Methods: We carried out a 12-week longitudinal clinical trial based on the treatment of AUD patients with naltrexone (N = 101), stratified by different alcohol metabolization genotypes. Genotyping was performed after the inclusion of the patients in the study, based on the individual presence of single nucleotide polymorphisms (SNPs) in the ADH (alcohol dehydrogenase)1B (ADH1B*2 and ADH1B*3), ADH1C (ADHC*1) and ALDH (aldehyde dehydrogenase) 2 (ALDH2*2) genes. The outcome of alcohol use has been monitored employing the timeline follow-back during the treatment. Results: The ADH1C*1 (Ile350Val, rs698) and ALDH2*2 (Glu504Lys, rs671) polymorphisms were associated with a better response to naltrexone treatment, whereas the ADH1B*3 (Arg370Cys, rs2066702) allelic variant showed a negative outcome. Conclusions: The present study explores a genomic setting for the treatment of AUD with naltrexone. According to our findings, the association between ADH1C*1 and ALDH2*2 variants and better outcomes suggests a successful treatment, whereas the ADH1B*3 mutated allele might lead to an unsuccessful treatment. Further studies should be performed to investigate the relationship between alcohol metabolizing genotypes, the family history of alcohol use disorders and the effect of naltrexone on the outcomes. Genotyping may be a valuable tool for precision-medicine and individualized approach, especially in the context of alcohol use disorders. The small number of subjects was the main limitation of the present study. MDPI 2021-10-10 /pmc/articles/PMC8533258/ /pubmed/34680127 http://dx.doi.org/10.3390/biom11101495 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Castaldelli-Maia, João M.
Malbergier, André
de Oliveira, Adriana B. P.
Amaral, Ricardo A.
Negrão, André B.
Gonçalves, Priscila D.
Ventriglio, Antonio
de Berardis, Domenico
de Antonio, Juliana
Firigato, Isabela
Gattás, Gilka J. F.
de Toledo Gonçalves, Fernanda
Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
title Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
title_full Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
title_fullStr Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
title_full_unstemmed Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
title_short Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder
title_sort exploring the role of alcohol metabolizing genotypes in a 12-week clinical trial of naltrexone for alcohol use disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533258/
https://www.ncbi.nlm.nih.gov/pubmed/34680127
http://dx.doi.org/10.3390/biom11101495
work_keys_str_mv AT castaldellimaiajoaom exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT malbergierandre exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT deoliveiraadrianabp exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT amaralricardoa exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT negraoandreb exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT goncalvespriscilad exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT ventriglioantonio exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT deberardisdomenico exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT deantoniojuliana exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT firigatoisabela exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT gattasgilkajf exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder
AT detoledogoncalvesfernanda exploringtheroleofalcoholmetabolizinggenotypesina12weekclinicaltrialofnaltrexoneforalcoholusedisorder